Publicação científica trimestral do CREMERJ - volume 3 - número 2 - 2024

82 Estado Atual do Tratamento do Câncer Colorretal Pedro Basilio Med. Ciên. e Arte , Rio de Janeiro, v.3, n.2, p.65-82, mai-ago 2024 26. Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322-334. PROSPECT TRIAL. 27. Bahadoer RR, Dijkstra EA, van Etten B, et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42. 28. Thompson HM, Omer DM, Lin S, et al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer TreatedWith Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMANetwOpen. 2024;7(1) :e2350903. doi:10.1001/jamanetworkopen.2023.50903 29. Habr-Gama A, de Souza PM, Ribeiro U Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087-1096. 30. Conroy T, Etienne P-L, Rio E, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of the PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023;41:LBA3504–LBA3504. 31. Cardelli S, Stocchi L, Merchea A, Colibaseanu D, DeLeon M, Mishra N, Hancock K, Larson DW Comparative Outcomes of Robotic Versus Open Proctectomy for Rectal Cancer at High Risk of Positive Circumferential Resection Margin. Diseases of the Colon & Rectum ():10.1097/DCR.0000000000003466, August 06, 2024.